Press Releases
Sharp Announces $650K Investment to Enhances IRT Solution
Sharp has announced a $650,000 investment into enhancing its Interactive Response Technology (IRT) solution. Sharp’s IRT solution is used to manage patient interactions and drug...
Press Releases
EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with CD30+ Stage IV Hodgkin Lymphoma
Takeda Pharmaceutical Co. announced that the EC extended the current marketing authorization of ADCETRIS to include treatment of adult patients with previously untreated CD30+ Stage...
Press Releases
Lonza Launches New Reliable, Robust and Customizable Pooled Donor Suspension Hepatocytes
Lonza announces the launch of DonorPlex Hepatocytes, a new line of high-quality cryopreserved pooled donor suspension hepatocytes, which are the first of their kind to...
Press Releases
MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease
MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating,...
Press Releases
Silgan Dispensing’s Iridya Addresses Unmet Patient Needs in Ophthalmic Drug Delivery Market
Silgan Dispensing, a global leader in the design, development and manufacturing of highly engineered pumps and sprayers in the pharmaceutical, home and beauty markets, will...
Press Releases
Marken To Build New GMP-Compliant Facility In Philadelphia
Marken announced the expansion of its facilities in Philadelphia to include more space for logistics operations as well as a new GMP-compliant storage and distribution...
Press Releases
Pexidartinib Granted Priority Review by FDA for Treatment of Tenosynovial Giant Cell Tumor
Daiichi Sankyo Company, Limited announced that the U.S. FDA has accepted a New Drug Application (NDA) and granted Priority Review for pexidartinib for the treatment...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.